Providing Hope for Parkinson’s Disease
Although formal clinical trial evaluations need to occur, novel research from McLean Hospital and Massachusetts General Hospital offers promising advances in Parkinson’s disease.
Press Release
Reprogramming a patient’s own skin cells to replace cells in the brain that are progressively lost during Parkinson’s disease has been shown to be technically feasible, reports a team of investigators from McLean Hospital and Massachusetts General Hospital in the most recent issue of The New England Journal of Medicine.
The Team
Bob Carter, MD, PhD
Massachusetts General Hospital
Todd Herrington, MD, PhD
Massachusetts General Hospital
Kwang-Soo Kim, PhD
McLean Hospital
Jeff Schweitzer, MD, PhD
Massachusetts General Hospital
Stay Updated!
The search for effective treatments for Parkinson’s disease is ongoing. Join our mailing list to stay up to date on the latest advances.
Related Content
Personalizing Stem Cell Therapy for Parkinson’s Disease
In the U.S. alone, as many as one million people have Parkinson’s disease. Kwang-Soo Kim, PhD, is committed to finding a way to lower those numbers.
First-in-Human Therapy With Stem Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease
MGH-McLean team have become the first to implant patient-derived midbrain dopaminergic progenitor cells into a patient with Parkinson’s.
